2invest AG (DB: 2INV)
Health Care · Biotechnology · DE
€7.94
-3.17% today · -38.0% 1Y
2invest AG (DB: 2INV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $50.97M.
Over the last twelve months the share price has lost 38.0%, trading between 6.56 and 13.40.
Tweenvest scores 2invest AG across four factors: quality 55/100, value 64/100, growth 100/100. Its strongest factor is growth.
2INV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $50.97M
- Revenue (TTM)
- $-1.88M
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- -0.02
- 52-week high
- €13.40
- 52-week low
- €6.56
- Avg volume (3M)
- —
- Shares outstanding
- 5.50M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.